XIFYRM Trademark

Trademark Overview

On Tuesday, October 31, 2023, a trademark application was filed for XIFYRM with the United States Patent and Trademark Office. The USPTO has given the XIFYRM trademark a serial number of 98248674. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Wednesday, May 6, 2026. This trademark is owned by Azurity Pharmaceuticals, Inc.. The XIFYRM trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, antirheumatics and antiphlogistics; pain relief medication
xifyrm

General Information

Serial Number98248674
Word MarkXIFYRM
Filing DateTuesday, October 31, 2023
Status819 - SU - REGISTRATION REVIEW COMPLETE
Status DateWednesday, May 6, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 9, 2024

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, antirheumatics and antiphlogistics; pain relief medication

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, November 13, 2023
Primary Code005
First Use Anywhere DateTuesday, July 15, 2025
First Use In Commerce DateTuesday, July 15, 2025

Trademark Owner History

Party NameAzurity Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWoburn, MA 01801
US
Party NameAzurity Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWoburn, MA 01801
US

Trademark Events

Event DateEvent Description
Monday, November 13, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, February 15, 2024ASSIGNED TO EXAMINER
Thursday, February 15, 2024NON-FINAL ACTION WRITTEN
Thursday, February 15, 2024NON-FINAL ACTION E-MAILED
Thursday, February 15, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, March 6, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 6, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 6, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, March 7, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 20, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 9, 2024PUBLISHED FOR OPPOSITION
Tuesday, April 9, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 4, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, June 10, 2024SOU TEAS EXTENSION RECEIVED
Monday, June 10, 2024SOU EXTENSION 1 FILED
Monday, June 10, 2024SOU EXTENSION 1 GRANTED
Thursday, June 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 4, 2025SOU TEAS EXTENSION RECEIVED
Friday, April 4, 2025SOU EXTENSION 2 FILED
Friday, April 4, 2025SOU EXTENSION 2 GRANTED
Saturday, April 5, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 19, 2025TEAS STATEMENT OF USE RECEIVED
Thursday, November 20, 2025SOU TEAS EXTENSION RECEIVED
Thursday, April 30, 2026CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, November 20, 2025SOU EXTENSION 3 FILED
Thursday, April 30, 2026SOU EXTENSION 3 GRANTED
Tuesday, August 19, 2025USE AMENDMENT FILED
Thursday, April 30, 2026STATEMENT OF USE PROCESSING COMPLETE
Friday, May 1, 2026NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 6, 2026ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, May 6, 2026NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

Related Keywords

xifyrm pain relief medication antiphlogistics antirheumatics preparations namely pharmaceutical